Swiss National Bank increased its holdings in Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) by 12.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,200 shares of the company’s stock after acquiring an additional 3,900 shares during the period. Swiss National Bank’s holdings in Rhythm Pharmaceuticals were worth $774,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC raised its holdings in shares of Rhythm Pharmaceuticals by 0.3% in the 2nd quarter. Janus Henderson Group PLC now owns 3,292,325 shares of the company’s stock worth $72,431,000 after acquiring an additional 10,556 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in Rhythm Pharmaceuticals by 172.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock valued at $1,391,000 after buying an additional 40,015 shares during the last quarter. Spark Investment Management LLC purchased a new stake in Rhythm Pharmaceuticals in the 1st quarter valued at about $1,060,000. Bank of America Corp DE increased its stake in Rhythm Pharmaceuticals by 116.3% in the 4th quarter. Bank of America Corp DE now owns 26,196 shares of the company’s stock valued at $704,000 after buying an additional 14,085 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at about $564,000. Institutional investors own 90.58% of the company’s stock.

NASDAQ:RYTM traded down $0.16 on Friday, hitting $22.78. The stock had a trading volume of 13,796 shares, compared to its average volume of 182,980. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.80 and a current ratio of 7.80. The stock has a market cap of $780.79 million, a P/E ratio of -9.53 and a beta of 0.65. Rhythm Pharmaceuticals Inc has a 1 year low of $18.00 and a 1 year high of $32.62. The firm’s fifty day simple moving average is $20.88 and its two-hundred day simple moving average is $24.39.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Monday, July 29th. The company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.36). Equities research analysts predict that Rhythm Pharmaceuticals Inc will post -4.16 EPS for the current year.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $43.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday. Stifel Nicolaus reiterated a “buy” rating and issued a $34.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, July 29th. BidaskClub lowered shares of Rhythm Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 7th. Finally, Canaccord Genuity assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, July 8th. They issued a “buy” rating and a $35.00 price objective for the company. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Rhythm Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $38.80.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Further Reading: What is Cost of Debt?

Want to see what other hedge funds are holding RYTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM).

Institutional Ownership by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.